Abstract
Historically, the evaluation of new, therapeutic strategies for cancer have depended exclusively on safety and clinical efficacy.[1] Today, there is an increasing recognition by health care providers and financing organizations of the resource constraints on the provision of these services, lending greater importance to their economic evaluation.[1]–[4] Further, as costs for such services continue to rise, there is also a heightened desire for information on the value for each dollar spent in providing these technologies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Schulman KA, Yabroff KR. Measuring the cost-effectiveness of cancer care. Oncology 1995; 9: 523–33.
Drummond MF, Stoddart GL, Torrance GW. Methods for Economic Evaluation of Health Care Programmes. New York: Oxford Medical Publications, 1987.
Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1991; 146:473–81.
NCI Economic Conference. 1994. The integration of economic outcome measures into NCI sponsored therapeutic trials. Bethesda, April 20–24.
NCI/ASCO Health Economics Working Group Workbook. Unpublished.
Eisenberg JM, Schulman KA, Glick HA, et al. Pharmacoeconomics: economic evaluation of Pharmaceuticals. In Pharmacoepidemiology (BL Strom ed). 2nd ed. Chincester, John Wiley & Sons, 1994.
Mauskopf J, Schulman K, Bell L, et al. A strategy for collecting phannacoeconomic data during phase II/III clinical trials. Pharmacoeconomics. 1996; 9(3): 264–77.
Schulman K-A, Yabroff KR, Glick H. A health services approach for the evaluation of innovative pharmaceutical and biotechnology products. Drug Inform J 1995; 29: 1405–14.
Hillner BE, Smith TJ, Desch CE. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: estimates using decision analysis while awaiting clinical trial results. J Am Med Assoc 1992; 269(15): 2055–61.
Schulman KA, Lynn LA, Glick HA, et al. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with HIV infection. Ann Intern Med. 1991; 114: 798–802.
O’Brien, B. Economic evaluation of Pharmaceuticals: Frankenstein’s monster or vampire of trials? Med Care 1996; 34: DS99–DS108.
Schulman KA, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Controlled Clin Trials 1996; 17: 304–15.
Finkler, SA. Cost accounting for health care organizations: concepts and applications. Gaithersburg, Maryland: Aspen Publishers, Inc., 1994.
Health Care Financing Administration. December 2, 1995. Revisions to payment policies and adjustments to the relative value units under the physician fee schedule for calendar year 1995; final rule. Federal Register.
St. Anthony’s UB-92 Editor: A guide to Medicare billing. Falconer CB, ed. Reston, Virginia: St. Anthony Publishing, 1994.
Glick HA, Polsky D, Wilke RJ, et al. Pharmacoeconomic analysis of tirilazad mesylate in patients with subarachnoid hemorrhage. Unpublished manuscript.
American Medical Association. 1993. Physicians’ Current Procedural Terminology, CPT-4-94. American Medical Association; Chicago.
Luce BR, Manning WG, Siegel JE, et al. “Estimating costs in cost-effectiveness analysis.” In Cost-effectiveness in Health and Medicine, New York: Oxford University Press, 1996.
The RED BOOK. Medical Economics Data. Montvale, VA: Medical Economics Company, Inc., 1995.
Revicki D, Irwin D, Reblando J, et al. The accuracy of self-reported disability days. Med Care 1994; 32:401–404.
Schulman KA, Glick HA, Yabroff KR et al. Introduction to clinical economics: assessment of cancer therapies. Monogr Natl Cancer Inst 1995; 19: 1–9.
Schulman KA, Dorsainvil D, Yabroff KR, et al. Prospective economic evaluation accompanying a trial of GM-CSF/IL-3 in patients undergoing autologous bone marrow transplant for Hodgkin’s and non-Hodgkin’s lymphoma. Bone Marrow Transplant 1998; 21:607–14.
Ihle JN. Biomedical and biological properties of interleukin-3: a lymphokine mediating the differentiation of a lineage of cells which includes prothymocytes and mast-like cells. J Immunol. 1983; 131: 282.
Goodman JW, Hall EA, Miller KL, et al. Interleukin-3 promotes erythroid burst formation in serum free cultures without detectable erythropoietin. Proc Nat Acad Sci, USA 1989; 128: 501–9.
Lopez AF, Dyson PG, To LB, et al. Recombinant human interleukin-3 stimulation ofhematopoiesis in humans: loss ofresponsiveness with differentiation in the neurtrophilic myeloid series. Blood 1988; 72: 1797–1804.
“American Nurses Association: 1994 average salaries.” In: Hospital and Health Care Report. Rochelle Park, NY: Wyatt Data Services.
National Association for Home Care. 1995. Basic Statistics About Home Care.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Kluwer Academic Publishers
About this chapter
Cite this chapter
Schulman, K.A., Boyko, W.L. (1998). Evaluating Cancer Costs in NCI Trials. In: Bennett, C.L., Stinson, T.J. (eds) Cancer Policy: Research and Methods. Cancer Treatment and Research, vol 97. Springer, Boston, MA. https://doi.org/10.1007/978-0-585-30498-4_4
Download citation
DOI: https://doi.org/10.1007/978-0-585-30498-4_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-7923-8203-4
Online ISBN: 978-0-585-30498-4
eBook Packages: Springer Book Archive